{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T09:12:18Z","timestamp":1790845938008,"version":"4.1.0"},"reference-count":29,"publisher":"Bentham Science Publishers Ltd.","issue":"11","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CCHTS"],"published-print":{"date-parts":[[2022,9]]},"abstract":"<jats:sec>\n<jats:title>:<\/jats:title>\n<jats:p>Infection by the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) provokes\nacute inflammation due to extensive replication of the virus in the epithelial cells of the upper\nand lower respiratory system.\nThe mammalian target of rapamycin (mTOR) is a l signalling protein with critical functions in cell\ngrowth, metabolism, and proliferation. It is known for its regulatory functions in protein synthesis and\nangiogenesis cascades. The structure of mTOR consists of two distinct complexes (mTORC1 and\nmTORC2) with diverse functions at different levels of the signalling pathway. By activating mRNA\ntranslation, the mTORC1 plays a key role in regulating protein synthesis and cellular growth. On the\nother hand, the functions of mTORC2 are mainly associated with cell proliferation and survival.\nBy using an appropriate inhibitor at the right time, mTOR modulation could provide immunosuppressive\nopportunities as antirejection regimens in organ transplantation as well as in the treatment\nof autoimmune diseases and solid tumours. The mTOR also has an important role in the inflammatory\nprocess. Inhibitors of mTOR might indeed be promising agents in the treatment of viral infections.\nThey have further been successfully used in patients with severe influenza A\/H1N1 pneumonia\nand acute respiratory failure. The officially accepted mTOR inhibitors that have undergone\nclinical testing are sirolimus, everolimus, temsirolimus, and tacrolimus. Thus, further studies on\nmTOR inhibitors for SARS-CoV-2 infection or COVID-19 therapy are well merited.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/1386207325666211130140923","type":"journal-article","created":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T04:56:54Z","timestamp":1638334614000},"page":"1805-1808","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Can We Use mTOR Inhibitors for COVID-19 Therapy?"],"prefix":"10.2174","volume":"25","author":[{"given":"Ina Y.","family":"Aneva","sequence":"first","affiliation":[{"name":"1Institute of Biodiversity and Ecosystem Research, Bulgarian Academy of Science, Sofia 1113, Bulgaria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hamid Reza Khayat","family":"Kashani","sequence":"first","affiliation":[{"name":"Department of Neurosurgery, Imam\nHossein Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Solomon","family":"Habtemariam","sequence":"additional","affiliation":[{"name":"Pharmacognosy Research Laboratories and Herbal Analysis Services, School of Science, University of Greenwich,\nCentral Avenue, Chatham-Maritime, Kent ME4 4TB, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maciej","family":"Banach","sequence":"additional","affiliation":[{"name":"Department of Hypertension, Chair of Nephrology\nand Hypertension, Medical University of Lodz, Lodz, Poland"},{"name":"Polish Mother\\'s Memorial Hospital Research Institute\n(PMMHRI), Lodz, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Parames C.","family":"Sil","sequence":"additional","affiliation":[{"name":"Division of Molecular Medicine, Bose Institute P-1\/12, CIT Scheme VII M, Kolkata 700054, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kasturi","family":"Sarkar","sequence":"additional","affiliation":[{"name":"Department of Microbiology, St. Xavier\\'s College, Kolkata, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adeleh","family":"Sahebnasagh","sequence":"additional","affiliation":[{"name":"Clinical Research Center, Department\nof Internal Medicine, North Khorasan University of Medical Sciences, Bojnurd, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad Amjad","family":"Kamal","sequence":"additional","affiliation":[{"name":"West China School of Nursing\n\/ Institutes for Systems Genetics, Frontiers Science Center for Disease-related Molecular Network, West China Hospital,\nSichuan University, Chengdu 610041, Sichuan, China"},{"name":"King Fahd Medical Research Center, King Abdulaziz University, P. O. Box 80216, Jeddah 21589, Saudi Arabia"},{"name":"Enzymoics; Novel Global Community Educational Foundation, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maryam","family":"Khayatkashani","sequence":"additional","affiliation":[{"name":"Amol University of Special Modern Technologies, Amol, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"960","DOI":"10.1016\/j.cell.2017.02.004","volume":"168","author":"Saxton R.A.","year":"2017","unstructured":"Saxton R.A.; Sabatini D.M.; mTOR signaling in growth, metabolism, and disease. Cell 2017,168(6),960-976","journal-title":"Cell"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/j.pharmthera.2013.12.004","volume":"142","author":"Polivka J.","year":"2014","unstructured":"Polivka J.; Janku F.; Molecular targets for cancer therapy in the PI3K\/AKT\/mTOR pathway. Pharmacol Ther 2014,142(2),164-175","journal-title":"Pharmacol Ther"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1099\/vir.0.19771-0","volume":"85","author":"Cooray S.","year":"2004","unstructured":"Cooray S.; The pivotal role of phosphatidylinositol 3-kinase-Akt signal transduction in virus survival. J Gen Virol 2004,85(Pt 5),1065-1076","journal-title":"J Gen Virol"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1099\/vir.0.82483-0","volume":"88","author":"Shin Y-K.","year":"2007","unstructured":"Shin Y-K.; Liu Q.; Tikoo S.K.; Babiuk L.A.; Zhou Y.; Effect of the phosphatidylinositol 3-kinase\/Akt pathway on influenza A virus propagation. J Gen Virol 2007,88(Pt 3),942-950","journal-title":"J Gen Virol"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1038\/nrmicro1855","volume":"6","author":"Buchkovich N.J.","year":"2008","unstructured":"Buchkovich N.J.; Yu Y.; Zampieri C.A.; Alwine J.C.; The TORrid affairs of viruses: Effects of mammalian DNA viruses on the PI3K-Akt-mTOR signalling pathway. Nat Rev Microbiol 2008,6(4),266-275","journal-title":"Nat Rev Microbiol"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1038\/nature04869","volume":"441","author":"Shaw R.J.","year":"2006","unstructured":"Shaw R.J.; Cantley L.C.; Ras, PI(3)K and mTOR signalling controls tumour cell growth. Nature 2006,441(7092),424-430","journal-title":"Nature"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1038\/nrg1879","volume":"7","author":"Engelman J.A.","year":"2006","unstructured":"Engelman J.A.; Luo J.; Cantley L.C.; The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism. Nat Rev Genet 2006,7(8),606-619","journal-title":"Nat Rev Genet"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"pe27","DOI":"10.1126\/scisignal.267pe27","volume":"2","author":"Alessi D.R.","year":"2009","unstructured":"Alessi D.R.; Pearce L.R.; Garc\u00eda-Mart\u00ednez J.M.; New insights into mTOR signaling: mTORC2 and beyond. Sci Signal 2009,2(67),pe27","journal-title":"Sci Signal"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1038\/nri2546","volume":"9","author":"Thomson A.W.","year":"2009","unstructured":"Thomson A.W.; Turnquist H.R.; Raimondi G.; Immunoregulatory functions of mTOR inhibition. Nat Rev Immunol 2009,9(5),324-337","journal-title":"Nat Rev Immunol"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"2655","DOI":"10.1111\/j.1600-6143.2009.02832.x","volume":"9","author":"S\u00e4emann M.D.","year":"2009","unstructured":"S\u00e4emann M.D.; Haidinger M.; Hecking M.; H\u00f6rl W.H.; Weichhart T.; The multifunctional role of mTOR in innate immunity: Implica-tions for transplant immunity. Am J Transplant 2009,9(12),2655-2661","journal-title":"Am J Transplant"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"2929","DOI":"10.1016\/j.molimm.2008.01.025","volume":"45","author":"Sun Q.","year":"2008","unstructured":"Sun Q.; Liu Q.; Zheng Y.; Cao X.; Rapamycin suppresses TLR4-triggered IL-6 and PGE(2) production of colon cancer cells by inhibit-ing TLR4 expression and NF-kappaB activation. Mol Immunol 2008,45(10),2929-2936","journal-title":"Mol Immunol"},{"key":"ref=12","author":"Duvoux C.","year":"2015","unstructured":"Duvoux C.; Toso C.;  2015"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"149","DOI":"10.4240\/wjgs.v12.i4.149","volume":"12","author":"Au K.P.","year":"2020","unstructured":"Au K.P.; Chok K.S.H.; Mammalian target of rapamycin inhibitors after post-transplant hepatocellular carcinoma recurrence: Is it too late? World J Gastrointest Surg 2020,12(4),149-158","journal-title":"World J Gastrointest Surg"},{"key":"ref=14","first-page":"327","volume":"34","author":"Conti P.","year":"2020","unstructured":"Conti P.; Ronconi G.; Caraffa A.; Gallenga C.E.; Ross R.; Frydas I.; Kritas S.K.; Induction of pro-inflammatory cytokines (IL-1 and IL-6) and lung inflammation by Coronavirus-19 (COVI-19 or SARS-CoV-2): Anti-inflammatory strategies. J Biol Regul Homeost Agents 2020,34(2),327-331","journal-title":"J Biol Regul Homeost Agents"},{"key":"ref=15","doi-asserted-by":"publisher","DOI":"10.1101\/2020.02.18.20024364","author":"Diao B.","year":"2020","unstructured":"Diao B.; Wang C.; Tan Y.; Chen X.; Liu Y.; Ning L.; Reduction and functional exhaustion of T cells in patients with coronavirus disease 2019 (COVID-19). Medrxiv 2020","journal-title":"Medrxiv"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1016\/S0140-6736(20)30183-5","volume":"395","author":"Huang C.","year":"2020","unstructured":"Huang C.; Wang Y.; Li X.; Ren L.; Zhao J.; Hu Y.; Zhang L.; Fan G.; Xu J.; Gu X.; Cheng Z.; Yu T.; Xia J.; Wei Y.; Wu W.; Xie X.; Yin W.; Li H.; Liu M.; Xiao Y.; Gao H.; Guo L.; Xie J.; Wang G.; Jiang R.; Gao Z.; Jin Q.; Wang J.; Cao B.; Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020,395(10223),497-506","journal-title":"Lancet"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1016\/j.arcmed.2020.08.002","volume":"51","author":"Sahebnasagh A.","year":"2020","unstructured":"Sahebnasagh A.; Mojtahedzadeh M.; Najmeddin F.; Najafi A.; Safdari M.; Rezai Ghaleno H.; Habtemariam S.; Berindan-Neagoe I.; Nabavi S.M.; A perspective on erythropoietin as a potential adjuvant therapy for acute lung injury\/acute respiratory distress syndrome in patients with covid-19. Arch Med Res 2020,51(7),631-635","journal-title":"Arch Med Res"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"1916","DOI":"10.1016\/S0140-6736(13)60903-4","volume":"381","author":"Chen Y.","year":"2013","unstructured":"Chen Y.; Liang W.; Yang S.; Wu N.; Gao H.; Sheng J.; Yao H.; Wo J.; Fang Q.; Cui D.; Li Y.; Yao X.; Zhang Y.; Wu H.; Zheng S.; Diao H.; Xia S.; Zhang Y.; Chan K.H.; Tsoi H.W.; Teng J.L.; Song W.; Wang P.; Lau S.Y.; Zheng M.; Chan J.F.; To K.K.; Chen H.; Li L.; Yuen K.Y.; Human infections with the emerging avian influenza A H7N9 virus from wet market poultry: Clinical analysis and char-acterisation of viral genome. Lancet 2013,381(9881),1916-1925","journal-title":"Lancet"},{"key":"ref=19","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1007\/s00281-017-0629-x","volume":"39","author":"Channappanavar R.","year":"2017","unstructured":"Channappanavar R.; Perlman S.; Pathogenic human coronavirus infections: Causes and consequences of cytokine storm and immuno-pathology. Semin Immunopathol 2017,39(5),529-539","journal-title":"Semin Immunopathol"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"205","DOI":"10.3851\/IMP2080","volume":"22","author":"Murray J.L.","year":"2012","unstructured":"Murray J.L.; McDonald N.J.; Sheng J.; Shaw M.W.; Hodge T.W.; Rubin D.H.; O\u2019Brien W.A.; Smee D.F.; Inhibition of influenza A virus replication by antagonism of a PI3K-AKT-mTOR pathway member identified by gene-trap insertional mutagenesis. Antivir Chem Chemother 2012,22(5),205-215","journal-title":"Antivir Chem Chemother"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.1128\/AAC.03659-14","volume":"59","author":"Kindrachuk J.","year":"2015","unstructured":"Kindrachuk J.; Ork B.; Hart B.J.; Mazur S.; Holbrook M.R.; Frieman M.B.; Traynor D.; Johnson R.F.; Dyall J.; Kuhn J.H.; Olinger G.G.; Hensley L.E.; Jahrling P.B.; Antiviral potential of ERK\/MAPK and PI3K\/AKT\/mTOR signaling modulation for Middle East respira-tory syndrome coronavirus infection as identified by temporal kinome analysis. Antimicrob Agents Chemother 2015,59(2),1088-1099","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"e01653","DOI":"10.1128\/JVI.01653-16","volume":"91","author":"Ye L.","year":"2017","unstructured":"Ye L.; Lee J.; Xu L.; Mohammed A.U.; Li W.; Hale J.S.; Tan W.G.; Wu T.; Davis C.W.; Ahmed R.; Araki K.; mTOR promotes anti-viral humoral immunity by differentially regulating CD4 helper T cell and B cell responses. J Virol 2017,91(4),e01653-e16","journal-title":"J Virol"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1111\/j.1600-6143.2010.03407.x","volume":"11","author":"Turner A.P.","year":"2011","unstructured":"Turner A.P.; Shaffer V.O.; Araki K.; Martens C.; Turner P.L.; Gangappa S.; Ford M.L.; Ahmed R.; Kirk A.D.; Larsen C.P.; Sirolimus enhances the magnitude and quality of viral-specific CD8+ T-cell responses to vaccinia virus vaccination in rhesus macaques. Am J Transplant 2011,11(3),613-618","journal-title":"Am J Transplant"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1097\/CCM.0b013e3182a2727d","volume":"42","author":"Wang C-H.","year":"2014","unstructured":"Wang C-H.; Chung F-T.; Lin S-M.; Huang S-Y.; Chou C-L.; Lee K-Y.; Lin T.Y.; Kuo H.P.; Adjuvant treatment with a mammalian target of rapamycin inhibitor, sirolimus, and steroids improves outcomes in patients with severe H1N1 pneumonia and acute respiratory failure. Crit Care Med 2014,42(2),313-321","journal-title":"Crit Care Med"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"1495","DOI":"10.1002\/jmv.26009","volume":"92","author":"Zheng Y.","year":"2020","unstructured":"Zheng Y.; Li R.; Liu S.; S. Immunoregulation with mTOR inhibitors to prevent COVID-19 severity: A novel intervention strategy beyond vaccines and specific antiviral medicines. J Med Virol 2020,92(9),1495-1500","journal-title":"J Med Virol"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1038\/s41421-020-0153-3","volume":"6","author":"Zhou Y.","year":"2020","unstructured":"Zhou Y.; Hou Y.; Shen J.; Huang Y.; Martin W.; Cheng F.; Network-based drug repurposing for novel coronavirus 2019-nCoV\/SARS-CoV-2. Cell Discov 2020,6(1),14","journal-title":"Cell Discov"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"1875","DOI":"10.1111\/ajt.15874","volume":"20","author":"Guillen E.","year":"2020","unstructured":"Guillen E.; Pineiro G.J.; Revuelta I.; Rodriguez D.; Bodro M.; Moreno A.; Campistol J.M.; Diekmann F.; Ventura-Aguiar P.; Case report of COVID-19 in a kidney transplant recipient: Does immunosuppression alter the clinical presentation? Am J Transplant 2020,20(7),1875-1878","journal-title":"Am J Transplant"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1097\/TP.0b013e3182421604","volume":"93","author":"Piao S.G.","year":"2012","unstructured":"Piao S.G.; Bae S.K.; Lim S.W.; Song J-H.; Chung B.H.; Choi B.S.; Yang C.W.; Drug interaction between cyclosporine and mTOR in-hibitors in experimental model of chronic cyclosporine nephrotoxicity and pancreatic islet dysfunction. Transplantation 2012,93(4),383-389","journal-title":"Transplantation"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1097\/FTD.0b013e3182399448","volume":"33","author":"Lam H.","year":"2011","unstructured":"Lam H.; Jeffery J.; Sitar D.S.; Aoki F.Y.; Oseltamivir, an influenza neuraminidase inhibitor drug, does not affect the steady-state phar-macokinetic characteristics of cyclosporine, mycophenolate, or tacrolimus in adult renal transplant patients. Ther Drug Monit 2011,33(6),699-704","journal-title":"Ther Drug Monit"}],"container-title":["Combinatorial Chemistry &amp; High Throughput Screening"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/1386207325666211130140923","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/198424\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/1386207325666211130140923","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,19]],"date-time":"2022-11-19T11:17:44Z","timestamp":1668856664000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/198424\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9]]},"references-count":29,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2022,9]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1386207325666211130140923","relation":{},"ISSN":["1386-2073"],"issn-type":[{"value":"1386-2073","type":"print"}],"subject":[],"published":{"date-parts":[[2022,9]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2021-07-14","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-09-27","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-10-08","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-09-21","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}